Genelux
GNLXGenelux Corporation is a late clinical-stage public company (Nasdaq: GNLX) developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogen …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2023-2025
All insider trades at Genelux
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 5/12/2025 | Sell | Smalling, Ralph | Head of Regulatory | $2.9 | $3,676 |
| 5/12/2025 | Sell | Cappello, Joseph | VP, Pharmaceutical Development | $2.9 | $13,832 |
| 5/12/2025 | Sell | Yu, Yong | VP, Clinical Trial Operations | $2.9 | $16,291 |
| 5/12/2025 | Sell | Zindrick, Thomas | President and CEO | $2.9 | $31,431 |
| 5/12/2025 | Sell | Ryder, Sean | General Counsel | $2.9 | $13,067 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)